Literature DB >> 15201693

New drugs to improve transplant outcomes.

M Roy First1, William E Fitzsimmons.   

Abstract

Fujisawa is committed to improving the outcomes of transplant patients worldwide. Research and development programs are underway for a new modified release dosage form of tacrolimus (MR-4), a new analog of leflunomide (FK 778), and several novel compounds (PG 490-88, AGI 1096) in collaboration with other companies. These programs are targeted to address many of the unmet medical needs in transplantation including (1) improving compliance, (2) reducing chronic rejection, and (3) improving long-term safety by reducing infectious and cardiovascular risk.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15201693     DOI： 10.1097/01.tp.0000126934.97815.2e

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


  9 in total

Review 1.  Immunotherapy for De Novo renal transplantation: what's in the pipeline?

Authors:  Helio Tedesco Silva; Paula Pinheiro Machado; Claudia Rosso Felipe; Jose Osmar Medina Pestana
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae).

Authors:  Anita M Brinker; Jun Ma; Peter E Lipsky; Ilya Raskin
Journal:  Phytochemistry       Date:  2007-01-23       Impact factor: 4.072

3.  Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking.

Authors:  Xin Chen; Takaya Murakami; Joost J Oppenheim; O M Zack Howard
Journal:  Blood       Date:  2005-06-14       Impact factor: 22.113

4.  Antibody-functionalized peptidic membranes for neutralization of allogeneic skin antigen-presenting cells.

Authors:  Yi Wen; Wen Liu; Christina Bagia; Shaojuan Zhang; Mingfeng Bai; Jelena M Janjic; Nick Giannoukakis; Ellen S Gawalt; Wilson S Meng
Journal:  Acta Biomater       Date:  2014-08-10       Impact factor: 8.947

5.  Comparable Renal Function at 6 Months with Tacrolimus Combined with Fixed-Dose Sirolimus or MMF: Results of a Randomized Multicenter Trial in Renal Transplantation.

Authors:  Eveline Van Gurp; Jesus Bustamante; Antonio Franco; Lionel Rostaing; Thomas Becker; Eric Rondeau; Zenon Czajkowski; Andrzej Rydzewski; Antonio Alarcon; Petr Bachleda; Jiri Samlik; Dirk Burmeister; Luis Pallardo; Marie-Christine Moal; Boleslaw Rutkowski; Zbigniew Wlodarczyk
Journal:  J Transplant       Date:  2010-10-05

Review 6.  Medication noncompliance and its implications in transplant recipients.

Authors:  Paul E Morrissey; Michelle L Flynn; Sonia Lin
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Clinical experience with once-daily tacrolimus in de novo kidney transplant recipients from living donors in Japan: 1-year follow up.

Authors:  Kenichiro Ishida; Shinichi Ito; Tomohiro Tsuchiya; Yoshinori Imanishi; Takashi Deguchi
Journal:  Cent European J Urol       Date:  2013-11-18

Review 8.  Immunosuppressive, anti-inflammatory and anti-cancer properties of triptolide: A mini review.

Authors:  Samira Ziaei; Reginald Halaby
Journal:  Avicenna J Phytomed       Date:  2016 Mar-Apr

9.  Medium-Term Renal Function in a Large Cohort of Stable Kidney Transplant Recipients Converted From Twice-Daily to Once-Daily Tacrolimus.

Authors:  Lluís Guirado; Dolores Burgos; Carme Cantarell; Ana Fernández; Antonio Franco; Miguel Ángel Gentil; Auxiliadora Mazuecos; Josep Vicenç Torregrosa; Ernesto Gómez Huertas; Juan Carlos Ruiz; Jaime Sánchez Plumed; Javier Paul; Ricardo Lauzurica; Sofía Zárraga; Antonio Osuna; Carlos Jiménez; Ángel Alonso; Alberto Rodríguez; Beatriz Bardají; Domingo Hernández
Journal:  Transplant Direct       Date:  2015-08-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.